HighTower Advisors LLC Has $162,000 Holdings in Standard BioTools Inc. (NASDAQ:LAB)

HighTower Advisors LLC boosted its stake in Standard BioTools Inc. (NASDAQ:LAB) by 13.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,791 shares of the company’s stock after buying an additional 10,690 shares during the quarter. HighTower Advisors LLC’s holdings in Standard BioTools were worth $162,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Intech Investment Management LLC acquired a new position in shares of Standard BioTools during the third quarter worth approximately $101,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Standard BioTools by 188.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock valued at $4,719,000 after purchasing an additional 1,597,728 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Standard BioTools by 86.3% in the third quarter. MetLife Investment Management LLC now owns 143,325 shares of the company’s stock valued at $277,000 after buying an additional 66,410 shares during the period. State Street Corp increased its holdings in Standard BioTools by 26.7% during the 3rd quarter. State Street Corp now owns 5,495,136 shares of the company’s stock worth $10,606,000 after purchasing an additional 1,157,984 shares in the last quarter. Finally, Wolverine Trading LLC acquired a new stake in shares of Standard BioTools in the 3rd quarter valued at about $27,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Standard BioTools Stock Performance

LAB opened at $1.07 on Friday. The firm has a market capitalization of $405.52 million, a PE ratio of -1.51 and a beta of 1.62. Standard BioTools Inc. has a 52-week low of $0.99 and a 52-week high of $3.04. The business’s 50-day simple moving average is $1.26 and its 200 day simple moving average is $1.65.

Insiders Place Their Bets

In related news, Director Casdin Partners Master Fund, L purchased 4,820,959 shares of the stock in a transaction on Friday, February 28th. The shares were purchased at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the acquisition, the director now directly owns 58,846,780 shares in the company, valued at $62,377,586.80. The trade was a 8.92 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 53.10% of the company’s stock.

Analysts Set New Price Targets

Separately, KeyCorp downgraded shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a report on Thursday, February 27th.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.